HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning Letter Prompts Be Natural Organics To Revise Web Claims

This article was originally published in The Rose Sheet

Executive Summary

The agency highlights claims for nine Be Natural Organics products – including statements about collagen production, cellular regeneration, hyperpigmentation reduction and eczema and acne treatment – in its recent warning letter to the company.

You may also be interested in...



FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

Skin 2 Spirit Scrubs Acne Claims On FDA Warning; Moon Valley Psoriasis Claim Persists

FDA’s warning letter to Skin 2 Sprit prompts a quick fix of website claims for the company’s skin care products. FDA advises Moon Valley Natural Products to correct claims that quality its skin care products as misbranded drugs.

FDA Warns Ayurvedic UMA Oils Brand For Claims Slip-Ups

UMA Oils must lose claims on its skin- and hair-care products regarding acne and eczema treatment, among others, if it intends to continue marketing them as cosmetics, FDA says in a July warning letter. The company touts its offerings as based on ancient Ayurvedic principles and five generations of family expertise.

Related Content

Topics

UsernamePublicRestriction

Register

RS121131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel